Mathematical modeling and parameter estimation of levodopa motor response in patients with parkinson disease.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
09
2019
accepted:
12
02
2020
entrez:
4
3
2020
pubmed:
4
3
2020
medline:
20
6
2020
Statut:
epublish
Résumé
Parkinson disease (PD) is characterized by a clear beneficial motor response to levodopa (LD) treatment. However, with disease progression and longer LD exposure, drug-related motor fluctuations usually occur. Recognition of the individual relationship between LD concentration and its effect may be difficult, due to the complexity and variability of the mechanisms involved. This work proposes an innovative procedure for the automatic estimation of LD pharmacokinetics and pharmacodynamics parameters, by a biologically-inspired mathematical model. An original issue, compared with previous similar studies, is that the model comprises not only a compartmental description of LD pharmacokinetics in plasma and its effect on the striatal neurons, but also a neurocomputational model of basal ganglia action selection. Parameter estimation was achieved on 26 patients (13 with stable and 13 with fluctuating LD response) to mimic plasma LD concentration and alternate finger tapping frequency along four hours after LD administration, automatically minimizing a cost function of the difference between simulated and clinical data points. Results show that individual data can be satisfactorily simulated in all patients and that significant differences exist in the estimated parameters between the two groups. Specifically, the drug removal rate from the effect compartment, and the Hill coefficient of the concentration-effect relationship were significantly higher in the fluctuating than in the stable group. The model, with individualized parameters, may be used to reach a deeper comprehension of the PD mechanisms, mimic the effect of medication, and, based on the predicted neural responses, plan the correct management and design innovative therapeutic procedures.
Identifiants
pubmed: 32126124
doi: 10.1371/journal.pone.0229729
pii: PONE-D-19-25770
pmc: PMC7053720
doi:
Substances chimiques
Antiparkinson Agents
0
Levodopa
46627O600J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0229729Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Eur J Neurosci. 2014 Feb;39(4):688-702
pubmed: 24313650
Comput Intell Neurosci. 2015;2015:187417
pubmed: 26640481
Prog Brain Res. 2010;183:275-97
pubmed: 20696325
Biochem Soc Trans. 2010 Apr;38(2):493-7
pubmed: 20298209
J Neurophysiol. 2000 Jul;84(1):289-300
pubmed: 10899204
Front Hum Neurosci. 2016 Jun 17;10:280
pubmed: 27378881
Science. 2008 Aug 8;321(5890):848-51
pubmed: 18687967
Nat Neurosci. 2007 Dec;10(12):1615-24
pubmed: 18026098
Brain. 2009 Feb;132(Pt 2):285-7
pubmed: 19168452
J Neurol. 2010 Nov;257(Suppl 2):S253-61
pubmed: 21080186
J Neurosci. 1997 Jun 15;17(12):4536-44
pubmed: 9169514
J Pharmacokinet Pharmacodyn. 2004 Jun;31(3):243-68
pubmed: 15518246
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Neurology. 1993 Feb;43(2):367-71
pubmed: 8437704
J Neurosci. 2008 Nov 19;28(47):12294-304
pubmed: 19020023
Clin Neuropharmacol. 1990 Feb;13(1):19-28
pubmed: 2306746
Science. 2005 Nov 25;310(5752):1337-40
pubmed: 16311337
Curr Opin Neurobiol. 2011 Jun;21(3):425-32
pubmed: 21550798
Nature. 2001 Sep 6;413(6851):67-70
pubmed: 11544526
Neural Netw. 2002 Jun-Jul;15(4-6):507-21
pubmed: 12371508
Conf Proc IEEE Eng Med Biol Soc. 2015;2015:6505-8
pubmed: 26737783
J Cogn Neurosci. 2005 Jan;17(1):51-72
pubmed: 15701239
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Clin Pharmacol Ther. 1979 Mar;25(3):358-71
pubmed: 761446
Cogn Affect Behav Neurosci. 2001 Jun;1(2):137-60
pubmed: 12467110
Behav Brain Res. 2009 Apr 12;199(1):141-56
pubmed: 18950662
Neural Netw. 2004 May;17(4):471-510
pubmed: 15109680
Ther Drug Monit. 2001 Dec;23(6):621-9
pubmed: 11802094
Sheng Li Xue Bao. 2012 Oct 25;64(5):543-9
pubmed: 23090495
Mov Disord. 2015 Jan;30(1):80-9
pubmed: 25488260
Mov Disord. 2005 Oct;20(10):1286-98
pubmed: 16001401
Cell Rep. 2012 Dec 27;2(6):1747-61
pubmed: 23246005
Prog Neurobiol. 1996 Nov;50(4):381-425
pubmed: 9004351
Ann Neurol. 1980 Dec;8(6):558-63
pubmed: 6260009
Brain Res. 2011 Nov 14;1423:96-113
pubmed: 22000081
Mov Disord. 2000 Jul;15(4):641-7
pubmed: 10928573
Neurology. 1994 Jul;44(7):1287-92
pubmed: 8035932
Eur J Neurosci. 2018 Jun;47(12):1563-1582
pubmed: 29786160